<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005878</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J9932, CDR0000067917</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J9932</secondary_id>
    <secondary_id>JHOC-99061108</secondary_id>
    <secondary_id>NCI-P00-0145</secondary_id>
    <nct_id>NCT00005878</nct_id>
  </id_info>
  <brief_title>Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus</brief_title>
  <official_title>Chemoprevention for Barrett's Esophagus Trial (CBET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. Celecoxib may be effective in preventing cancer in&#xD;
      patients with Barrett's esophagus.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing&#xD;
      cancer in patients who have Barrett's esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in&#xD;
           patients with low or high-grade dysplasia of the esophagus.&#xD;
&#xD;
      OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter study.&#xD;
      Patients are stratified according to center and grade of dysplasia at baseline (low vs high).&#xD;
      Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in&#xD;
           the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus&#xD;
           or cancer at other sites.&#xD;
&#xD;
      Patients are followed at 12 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed Barrett's dysplasia with specific information on the location&#xD;
             (level) of the highest grade of dysplasia based on biopsy from baseline endoscopy&#xD;
&#xD;
               -  Short segment Barrett's esophagus must be sufficient area to allow for biopsy&#xD;
                  without complete resection&#xD;
&#xD;
          -  No presence of reflux esophagitis grades 2-4&#xD;
&#xD;
          -  No history of confirmed invasive carcinoma of the esophagus&#xD;
&#xD;
          -  No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm&#xD;
             or more in diameter within the past 30 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  No significant bleeding disorder&#xD;
&#xD;
          -  No other abnormal hematopoietic laboratory test result that would preclude study&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT less than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase less than 1.5 times ULN&#xD;
&#xD;
          -  No chronic or acute hepatic disorder&#xD;
&#xD;
          -  No abnormal hepatic laboratory test result that would preclude study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No chronic or acute renal disorder&#xD;
&#xD;
          -  No other abnormal renal laboratory test result that would preclude study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or&#xD;
             ulcerative colitis)&#xD;
&#xD;
          -  No other prior or concurrent curatively treated malignancy with a survival prognosis&#xD;
             of less than 5 years&#xD;
&#xD;
          -  No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib),&#xD;
             sulfonamides, salicylates, or NSAIDs&#xD;
&#xD;
          -  No other significant medical, psychological, or psychosocial condition that would&#xD;
             preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous&#xD;
             corticosteroids&#xD;
&#xD;
          -  At least 6 months since prior regular (at least 4 weeks duration) inhaled&#xD;
             corticosteroids&#xD;
&#xD;
          -  No concurrent regular oral or intravenous corticosteroids&#xD;
&#xD;
          -  No concurrent regular inhaled corticosteroids&#xD;
&#xD;
          -  Concurrent corticosteroid nasal spray allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 12 weeks since prior radiotherapy to the chest or upper abdomen&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 months since prior surgery to the esophagus or stomach except hiatal hernia&#xD;
             repair, fundoplication, vagotomy, or pyloroplasty&#xD;
&#xD;
          -  No prior complete mucosal resection using any technique&#xD;
&#xD;
          -  No concurrent resection of high-grade nodule&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior chronic (at least 3 times a week for greater than 2&#xD;
             weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater&#xD;
             than 100 mg/day)&#xD;
&#xD;
          -  No prior complete mucosal ablation using any technique&#xD;
&#xD;
          -  No prior treatment on this study&#xD;
&#xD;
          -  At least 30 days since prior investigational medication including shingles vaccine&#xD;
&#xD;
          -  No concurrent chronic NSAIDs or COX-2 inhibitors except low-dose aspirin (i.e., no&#xD;
             greater than 100 mg/day)&#xD;
&#xD;
          -  No concurrent anticoagulants (e.g., heparin or warfarin)&#xD;
&#xD;
          -  No other concurrent investigational medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arlene A. Forastiere, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA; Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):545-57. doi: 10.1093/jnci/djk112.</citation>
    <PMID>17405999</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

